<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562627</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003030-41</org_study_id>
    <secondary_id>EudraCT 2007-003030-41</secondary_id>
    <secondary_id>REK 1.2007.1603</secondary_id>
    <nct_id>NCT00562627</nct_id>
  </id_info>
  <brief_title>Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty</brief_title>
  <official_title>Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asker &amp; Baerum Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asker &amp; Baerum Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty (TKA) is associated with moderate to severe postoperative pain,
      causing patient discomfort, mobilisation and hospital discharge.

      The aim of this study is to:

        1. Compare analgetic efficacy of to types of local infiltration analgesia in total knee
           arthroplasty.

        2. Compare analgetic efficacy of local infiltration analgesia with continuous epidural
           analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total knee arthroplasty (TKA) is increasingly common in the treatment of knee osteoarthritis.
      TKA is associated with moderate to severe postoperative pain, causing patient discomfort,
      mobilisation and hospital discharge.

      Continuous epidural analgesia is often used for controlling pain after TKA. Recent studies
      describe a new method for pain control after total knee arthroplasty which consists of local
      infiltration with local anesthetics and adrenaline. This infiltrations can be combined with
      ketorolac and/or morphine. The aim of this study is to:

        1. Compare analgetic efficacy of to types of local infiltration analgesia in total knee
           arthroplasty.

        2. Compare analgetic efficacy of local infiltration analgesia with continuous epidural
           analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain at Rest (VAS)</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>VAS (pain at rest) 0-100 mm. VAS 0 mm means no pain and VAS 100 mm means maximal pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>Morphine used by patient controlled analgesia. Amount of used morphine during the first 48 hours after surgery were documented in the CRF by the pain nurses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Readiness for Discharge</measure>
    <time_frame>up to 10 days postoperative</time_frame>
    <description>Each postoperative day, discharge readiness was assessed by an orthopaedic surgeon, a pain nurse, a ward nurse, and a physiotherapist according to the following criteria: no evidence for surgical complications, VAS pain at rest ≤30 mm which is controlled by oral analgesics, ability to eat and drink, ability to walk with elbow crutches, and ability to climb ≥8 stairs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>LIA IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIA IA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard continuous epidural analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <description>intraoperative and 1. postoperative day</description>
    <arm_group_label>LIA IV</arm_group_label>
    <arm_group_label>LIA IA</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adrenaline</intervention_name>
    <description>intraoperative LIA (IV and IA) and continuous EDA</description>
    <arm_group_label>LIA IV</arm_group_label>
    <arm_group_label>LIA IA</arm_group_label>
    <arm_group_label>EDA</arm_group_label>
    <other_name>Adrenalin</other_name>
    <other_name>(epinephrine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac</intervention_name>
    <description>intraoperative and 1. postoperative day</description>
    <arm_group_label>LIA IV</arm_group_label>
    <arm_group_label>LIA IA</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine</intervention_name>
    <description>intraoperative</description>
    <arm_group_label>LIA IV</arm_group_label>
    <arm_group_label>LIA IA</arm_group_label>
    <other_name>Morfin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>continuous postoperatively</description>
    <arm_group_label>EDA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine</intervention_name>
    <description>continuous postoperatively</description>
    <arm_group_label>EDA</arm_group_label>
    <other_name>Marcain</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients at least 18 years of age

          -  scheduled for elective total knee arthroplasty

          -  ASA I-III

          -  signed written informed consent

        Exclusion Criteria:

          -  age &lt; 18

          -  ASA &gt; III

          -  moderate or severe cardiac disease, bronchial asthma

          -  allergy against ropivacaine, ketorolac or morphine

          -  analgetic abuse

          -  pregnancy or nursing women

          -  severe psychiatric disease

          -  moderate to severe dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich J Spreng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asker and Baerum Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asker and Baerum Hospital</name>
      <address>
        <city>Rud</city>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <results_first_submitted>May 24, 2011</results_first_submitted>
  <results_first_submitted_qc>August 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2011</results_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ulrich Johannes Spreng</name_title>
    <organization>Asker and Baerum Hospital</organization>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee arthroplasty</keyword>
  <keyword>local infiltration analgesia</keyword>
  <keyword>TKA</keyword>
  <keyword>epidural analgesia</keyword>
  <keyword>operation</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LIA IV (Local Infiltration Analgesia, Intravenous)</title>
          <description>Local infiltration analgesia with 150 mg ropivacaine and 0.5 mg adrenaline and intravenous 30 mg ketorolac and 5mg morphine</description>
        </group>
        <group group_id="P2">
          <title>LIA IA, (Local Infiltration Analgesia, Intra-articular)</title>
          <description>Local infiltration analgesia with 150 mg ropivacaine, 0.5 mg adrenaline and 30 mg ketorolac and 5 mg morphine</description>
        </group>
        <group group_id="P3">
          <title>Epidural</title>
          <description>continuous epidural analgesia with fentanyl 2 ug/ml, bupivacaine 1mg/ml and epinephrine 1 ug/ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LIA IV (Local Infiltration Analgesia, Intravenous)</title>
          <description>Local infiltration analgesia with 150 mg ropivacaine and 0.5 mg adrenaline and intravenous 30 mg ketorolac and 5mg morphine</description>
        </group>
        <group group_id="B2">
          <title>LIA IA, (Local Infiltration Analgesia, Intra-articular)</title>
          <description>Local infiltration analgesia with 150 mg ropivacaine, 0.5 mg adrenaline and 30 mg ketorolac and 5 mg morphine</description>
        </group>
        <group group_id="B3">
          <title>Epidural</title>
          <description>continuous epidural analgesia with fentanyl 2 ug/ml, bupivacaine 1mg/ml and epinephrine 1 ug/ml</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="11"/>
                    <measurement group_id="B2" value="67.2" spread="8.9"/>
                    <measurement group_id="B3" value="65.8" spread="10.7"/>
                    <measurement group_id="B4" value="66.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Use</title>
        <description>Morphine used by patient controlled analgesia. Amount of used morphine during the first 48 hours after surgery were documented in the CRF by the pain nurses.</description>
        <time_frame>48 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LIA IV (Local Infiltration Analgesia, Intravenous)</title>
            <description>Local infiltration analgesia with 150 mg ropivacaine and 0.5 mg adrenaline and intravenous 30 mg ketorolac and 5mg morphine</description>
          </group>
          <group group_id="O2">
            <title>LIA IA, (Local Infiltration Analgesia, Intra-articular)</title>
            <description>Local infiltration analgesia with 150 mg ropivacaine, 0.5 mg adrenaline and 30 mg ketorolac and 5 mg morphine</description>
          </group>
          <group group_id="O3">
            <title>Epidural</title>
            <description>continuous epidural analgesia with fentanyl 2 ug/ml, bupivacaine 1mg/ml and epinephrine 1 ug/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Use</title>
          <description>Morphine used by patient controlled analgesia. Amount of used morphine during the first 48 hours after surgery were documented in the CRF by the pain nurses.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="39"/>
                    <measurement group_id="O2" value="49" spread="36"/>
                    <measurement group_id="O3" value="54" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain at Rest (VAS)</title>
        <description>VAS (pain at rest) 0-100 mm. VAS 0 mm means no pain and VAS 100 mm means maximal pain.</description>
        <time_frame>48 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LIA IV (Local Infiltration Analgesia, Intravenous)</title>
            <description>Local infiltration analgesia with 150 mg ropivacaine and 0.5 mg adrenaline and intravenous 30 mg ketorolac and 5mg morphine</description>
          </group>
          <group group_id="O2">
            <title>LIA IA, (Local Infiltration Analgesia, Intra-articular)</title>
            <description>Local infiltration analgesia with 150 mg ropivacaine, 0.5 mg adrenaline and 30 mg ketorolac and 5 mg morphine</description>
          </group>
          <group group_id="O3">
            <title>Epidural</title>
            <description>continuous epidural analgesia with fentanyl 2 ug/ml, bupivacaine 1mg/ml and epinephrine 1 ug/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Pain at Rest (VAS)</title>
          <description>VAS (pain at rest) 0-100 mm. VAS 0 mm means no pain and VAS 100 mm means maximal pain.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="15"/>
                    <measurement group_id="O2" value="12" spread="13"/>
                    <measurement group_id="O3" value="30" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Readiness for Discharge</title>
        <description>Each postoperative day, discharge readiness was assessed by an orthopaedic surgeon, a pain nurse, a ward nurse, and a physiotherapist according to the following criteria: no evidence for surgical complications, VAS pain at rest ≤30 mm which is controlled by oral analgesics, ability to eat and drink, ability to walk with elbow crutches, and ability to climb ≥8 stairs.</description>
        <time_frame>up to 10 days postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LIA IV (Local Infiltration Analgesia, Intravenous)</title>
            <description>Local infiltration analgesia with 150 mg ropivacaine and 0.5 mg adrenaline and intravenous 30 mg ketorolac and 5mg morphine</description>
          </group>
          <group group_id="O2">
            <title>LIA IA, (Local Infiltration Analgesia, Intra-articular)</title>
            <description>Local infiltration analgesia with 150 mg ropivacaine, 0.5 mg adrenaline and 30 mg ketorolac and 5 mg morphine</description>
          </group>
          <group group_id="O3">
            <title>Epidural</title>
            <description>continuous epidural analgesia with fentanyl 2 ug/ml, bupivacaine 1mg/ml and epinephrine 1 ug/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Readiness for Discharge</title>
          <description>Each postoperative day, discharge readiness was assessed by an orthopaedic surgeon, a pain nurse, a ward nurse, and a physiotherapist according to the following criteria: no evidence for surgical complications, VAS pain at rest ≤30 mm which is controlled by oral analgesics, ability to eat and drink, ability to walk with elbow crutches, and ability to climb ≥8 stairs.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.3"/>
                    <measurement group_id="O2" value="3.5" spread="0.7"/>
                    <measurement group_id="O3" value="5.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LIA IV (Local Infiltration Analgesia, Intravenous)</title>
          <description>Local infiltration analgesia with 150 mg ropivacaine and 0.5 mg adrenaline and intravenous 30 mg ketorolac and 5mg morphine</description>
        </group>
        <group group_id="E2">
          <title>LIA IA, (Local Infiltration Analgesia, Intra-articular)</title>
          <description>Local infiltration analgesia with 150 mg ropivacaine, 0.5 mg adrenaline and 30 mg ketorolac and 5 mg morphine</description>
        </group>
        <group group_id="E3">
          <title>Epidural</title>
          <description>continuous epidural analgesia with fentanyl 2 ug/ml, bupivacaine 1mg/ml and epinephrine 1 ug/ml</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ulrich Johannes Spreng</name_or_title>
      <organization>Baerum Hospital</organization>
      <phone>004798499184</phone>
      <email>ulispreng@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

